Immunogenicity and Safety of a 2 + 1 DTPa Priming Schedule in Australian Infants and the Impact of Maternally Derived Antibodies on Pertussis Antibody Responses up to 4 Years of Age
We assessed the impact of maternally derived pertussis antibodies on infant responses to a 2 + 1 vaccine schedule (6 weeks, 12 weeks, and 12 months). Infants with baseline antibodies showed lower IgG responses following the primary vaccination series, but this did not impair booster responses at 4 years of age. Clinical Trials: The study is registered on the Australian New Zealand Clinical Trials Registry - www.anzctr.org.au (Part 1: ACTRN12615000898550, Part 2: ACTRN12622001216707).
Authors
- Peter McIntyre (ORCID: https://orcid.org/0000-0001-5808-7450)
- Anita H.J. van den Biggelaar (ORCID: https://orcid.org/0000-0002-3323-7261)
- Sonia McAlister (ORCID: https://orcid.org/0000-0002-0384-2372)
- Ruth B. Thornton (ORCID: https://orcid.org/0000-0001-9852-8310)
- Peter Richmond (ORCID: https://orcid.org/0000-0001-7562-7228)
- Matthew N. Cooper (ORCID: https://orcid.org/0000-0003-1139-3682)
- Nicholas William Wood (ORCID: https://orcid.org/0000-0002-9500-3348)
- Alexandra Dierig
Institutions
- The University of Sydney (AU)
- The Kids Research Institute Australia (AU)
- The University of Western Australia (AU)
- Princess Margaret Hospital for Children (AU)
- Government of Western Australia Department of Health (AU)
- Children's Hospital at Westmead (AU)
- Queen Elizabeth II Medical Centre (AU)
- Children’s Health Queensland Hospital and Health Service (AU)
- National Centre for Immunisation Research & Surveillance (AU)
Publication Details
- Journal
- Journal of the Pediatric Infectious Diseases Society
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1093/jpids/piaf067
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 0.00